End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.68 CNY | -1.79% | -6.56% | -14.77% |
Apr. 22 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 11 | Zhongsheng Pharma's Chairman to Raise Stake in Company | MT |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
Weaknesses
- With an expected P/E ratio at 29.11 and 26.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.77% | 1.6B | - | C | |
+38.51% | 727B | C+ | ||
+33.05% | 599B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+16.00% | 243B | B+ | ||
+8.09% | 205B | B- | ||
-5.77% | 203B | A+ | ||
+6.19% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002317 Stock
- Ratings Guangdong Zhongsheng Pharmaceutical Co., Ltd.